Monopar Therapeutics(MNPR) - 2021 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Delaware 32-0463781 (I.R.S. employer For the transition period from to identification number) Commission File Number: 001-39070 (Mark One) MONOPAR THERAPEUTICS INC. ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of registrant as specified in its charter) (State or other jurisdiction ...